Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

COSCIENS Biopharma Inc T.AEZ


Primary Symbol: T.AEZS

COSCIENS Biopharma Inc., formerly Aeterna Zentaris Inc., is a specialty biopharmaceutical company engaged in the development and commercialization of a diverse portfolio of pharmaceutical and diagnostic products, including those focused on areas of unmet medical need. Its lead product, macimorelin (Macrilen; Ghryvelin), is an oral test indicated for the diagnosis of adult growth hormone deficiency (AGHD). The Company is also engaged in the development of therapeutic assets and proprietary extraction technology, which is applied to the production of active ingredients from renewable plant resources used in cosmeceutical products (i.e., oat beta glucan and avenanthramides, which are found in skincare product brands like Aveeno and Burt’s Bees formulations) and being developed as potential nutraceuticals and/or pharmaceuticals.


TSX:AEZS - Post by User

Bullboard Posts
Comment by TechTargeton Nov 25, 2015 1:49pm
105 Views
Post# 24324914

RE:RE:RE:ridiculous

RE:RE:RE:ridiculous Not ridiculous at all!  When there are wild swings in price, the regulators ask the companies if they have any development to share and the company simply responded no.

If you follow this stock, you'll see, it was pushed down on the scare of the reverse split (look at the board for proof).  

I was a lone voice here saying that.  They needed to consolidate to not only stay listed but also attract new, larger investors (who don't play with penny stocks).

Investors on this got raped on the way down, at the split and again later.  Those who held tight are back at $13 (which is equivalent to the old .13 cents).

Now this thing is out of penny stock territory, we have bigger players coming in because they can buy the stock but could not before.  Institutions and large funds can't buy stock that trade below a certain price (sub 10 cents is a wasteland for large buyers).

Now that the dust is settling down, someone should call the company to ask them if they plan to leverage the attention they are getting.  If they do, the SP will continue to go up, if they don't, my stop loss is in place...
Bullboard Posts